Kintor Pharmaceutical Company Description
Kintor Pharmaceutical Limited, a clinical-stage novel drug developer, focuses on developing small molecules and biologic drugs for dermatology and oncology in the People’s Republic of China.
Its product candidates include KX-826, a potential topical drug for the treatment of androgenic alopecia (AGA) and acne vulgaris, which is in phase III clinical trial; and GT20029, a topical AR-PROTAC compound for the treatment of AGA and acne vulgaris that is in phase II clinical trial.
The company is developing GT1708F (Hedgehog/SMO Inhibitor), an inhibitor of the hedgehog signal transduction pathway to treat idiopathic pulmonary fibrosis, and blood cancer; GT0486, an inhibitor of the PI3K/mTOR signalling pathway and a second generation mTOR inhibitor for the treatment of metastatic solid tumours, such as breast cancer, prostate cancer, and hepatocellular carcinoma (HCC); and ALK-1 Antibody (GT90001), an anti-angiogenesis inhibitor and targets a new biological target activin receptor-like kinase-1 globally to treat metastatic hepatocellular carcinoma, a common type of liver cancer, and a variety of solid tumours.
Kintor Pharmaceutical Limited was founded in 2009 and is headquartered in Suzhou, the People’s Republic of China.
| Country | Cayman Islands |
| Founded | 2009 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 168 |
| CEO | Youzhi Tong |
Contact Details
Address: Suzhou Industrial Park Suzhou, 215123 China | |
| Phone | 86 51 2626 39909 |
| Website | kintor.com.cn |
Stock Details
| Ticker Symbol | KNTPF |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | CNY |
| ISIN Number | KYG5273B1077 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Youzhi Tong | Founder, Chief Executive Officer and Executive Chairman |
| Dr. Xiang Ni | Chief Medical Officer and Executive Director |
| Ming Ming Cheung | Joint Company Secretary and Chief Financial Officer |
| Wai Chiu Wong C.P.A., CTP, FCS | Company Secretary |